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Anti-glomerular basement membrane (anti-GBM)-induced
glomerulonephritis involves T-helper type 1 (Th1) responses
leading to rapid crescent formation. As many inflammatory
and immune responses in general are affected by histamine,
we examined the effects of histaminergic ligands on immune
renal injury in the rat. Female Wistar-Kyoto rats were injected
intraperitoneally with an antibody against the GBMs.
Histaminergic ligands were then injected twice daily for
5 days after which renal function was assessed by
proteinuria. Treatment with histamine led to significant dose-
dependent reductions in proteinuria compared to the control
antibody-injected group and markedly decreased the
number of crescentic glomeruli and macrophage infiltration
of the glomeruli. Furthermore, histamine significantly
decreased the plasma concentration of interleukin-12, a
Th1-type cytokine compared to the antibody-injected control
animals. Dimaprit, an H2/H4 agonist, mimicked the effects of
histamine on proteinuria and crescent formation. Clozapine,
an H4 agonist, tended to mimic the effects of histamine,
whereas an H1, mepyramine, or an H2 antagonist, ranitidine,
did not reverse the protective effect of histamine. We suggest
that histamine may alleviate renal injury in anti-GBM
glomerulonephritis by suppressing the immune response.
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Anti-glomerular basement membrane (anti-GBM) glomer-
ulonephritis progresses with crescent formation rapidly, and
T-helper type 1 (Th1) responses are closely related to the
pathogenesis and progression of this disease.1–4 The infiltra-
tion of inflammatory cells, such as macrophages and
T lymphocytes, is a predominant factor in the development
of anti-GBM glomerulonephritis. In contrast, T-helper type 2
(Th2) cytokines, such as interleukin (IL)-4 and IL-10, have
been reported to attenuate the development of anti-GBM
glomerulonephritis in mice by preventing production and
function of Th1 cytokines.4–7
Histamine is stored within secretory granules of mast cells
and basophils. The release of histamine, which is initiated in
response to specific antigens, causes an increase in capillary
permeability and edema formation. These inflammatory
responses are mediated predominantly by histamine H1
receptors.8 Conversely, histamine H2 receptor stimulation has
been shown to suppress immune responses by reducing the
chemotactic responsiveness of leukocytes and inflammatory
cytokines.9 Whereas histamine H3 receptors are expressed
primarily in the brain, histamine H4 receptors are expressed
in peripheral tissues, particularly, those of hematopoietic
lineage, such as bone marrow, spleen, thymus, and leuko-
cytes.10 Histamine H4 receptors are also involved in the
regulation of immune responses and in inflammatory cell
recruitment.11 Thus, it is likely that histaminergic ligands
exert an influence on the development of glomerular
immune injury.
In this study, we employed an animal model of anti-GBM
glomerulonephritis induced by an intraperitoneal injection of
a monoclonal antibody directed against the NC1 domain of
type IV collagen. This animal model is a passive antibody-
dependent model of anti-GBM glomerulonephritis and
different from that of accelerated anti-GBM glomerulone-
phritis, which depends on active immune responses to
deposited heterologous antibodies specific for the GBM.
However, passive transfer of the anti-GBM antibody has been
shown to induce glomerulonephritis similar to that seen in
actively immunized rats, although the magnitude of damage
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is less severe.12 Using this animal model, we evaluated
the effects of histaminergic ligands on functional and
morphologic outcomes.
RESULTS
Effects of histamine
No animal died during the 6-day period between adminis-
tration of anti-GBM antibody and killing. Systolic blood
pressure did not differ significantly among groups 6 days
after antibody injection, and no marked difference was found
in the plasma levels of blood urea nitrogen and creatinine
(Table 1 and Figure 1).
Endocapillary proliferation, severe fibrinoid necrosis, and
marked crescent formation were identified 6 days after
antibody injection (Figure 2a). Histamine decreased the
number of crescent glomeruli in a dose-dependent manner
(Figure 2b and c). The percentages of crescentic glomeruli in
the histamine (20 mg/kg)-treated and histamine (50 mg/kg)-
treated groups were 47 and 15%, respectively, of that in the
antibody-injected control group.
Immunofluorescence showed linear deposition of anti-
body along the GBM in animals injected with antibody
(Figure 3). Likewise, antibody deposition was observed in
animals treated with histamine twice a day (20 mg/kg, each).
The intensity of immunofluorescence was similar between
the two groups. On the other hand, no deposition of
complement C3 was shown in glomeruli in either the
antibody-injected or histamine-treated group.
Immunohistochemistry showed no ED-1-positive cells
(rat macrophages) in glomeruli of intact animals. Injection
of anti-GBM antibody recruited macrophages to glomeruli
(Figure 4a), and the number of macrophages in 50 glomeruli
was 3677101 (mean7s.d., n¼ 7). Treatments with hista-
mine decreased the number of macrophages (Figure 4b). The
number of macrophages in 50 glomeruli in the histamine
(20 mg/kg)-treated group was 217763 (n¼ 5) (Po0.05).
Table 1 | Laboratory data and systolic blood pressure
Blood urea
nitrogen (mg/dl)
Creatinine
(mg/dl)
Blood
pressure (mg/dl)
Intact group 11.971.1 0.2070.02 10276
Antibody-injected group 13.273.0 0.2070.01 110711
Histamine-treated 11.572.4 0.1970.01 112712
antibody-injected group
GBM, glomerular basement membrane.
Following the measurement of blood pressure 6 days after anti-GBM antibody
injection, blood was collected and analyzed with routine laboratory procedures.
Values represent the mean7s.d. of five animals.
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Figure 1 | Experimental procedures. After an intraperitoneal
injection of anti-GBM antibody, saline or histaminergic ligands were
subcutaneously administered twice a day for 5 days. Urine samples
for 24 h were collected 5–6 days after antibody injection. Then,
kidneys were dissected for histology and immunohistochemistry.
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Figure 2 | Representative photomicrographs of periodic acid-
Schiff stain and determination of the percentage of crescentic
glomeruli. (a) Six days after injection of anti-GBM antibody,
endocapillary proliferation, severe necrosis, and marked crescent
formation were seen in glomeruli. (b) In glomeruli from an animal
treated with histamine (20 mg/kg) twice a day, endocapillary
proliferation was segmental and mild, and crescent formation was
rare. (c) The percentage of crescentic glomeruli was determined 6
days after antibody injection. Values represent the mean7s.d. of
5–8 animals. *Po0.01 as compared to the antibody-injected control
group. Bar¼ 100 mm.
a b
Figure 3 | Representative photomicrographs of direct
immunofluorescence of fluorescein isothiocyanate-conjugated
anti-rat IgG. (a) Six days after injection of anti-GBM antibody, linear
deposition of antibody along the GBM was observed in glomeruli.
(b) In glomeruli from an animal treated with histamine (20 mg/kg)
twice a day, deposition of antibody was similar to that in
antibody-injected control glomeruli. Bar¼ 100 mm.
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Antibody injection induced proteinuria in control animals
5–6 days after injection. Daily treatments with histamine
dose-dependently ameliorated the severity of proteinuria
(Figure 5). The extents of proteinuria in the histamine
(20 mg/kg)-treated and histamine (50 mg/kg)-treated groups
were 28 and 5%, respectively, of that in the antibody-injected
control group.
The plasma concentration of IL-12, a Th1 cytokine,
was 6207117 pg/ml (mean7s.d., n¼ 5) in intact animals.
The IL-12 concentration increased to 8807134 pg/ml (n¼ 5)
6 days after anti-GBM antibody injection. Treatments with
histamine twice a day for 5 days (20 mg/kg, each) decreased
the IL-12 level to 572760 pg/ml (n¼ 5) (Po0.01).
Effects of histamine receptor agonists
Administration of dimaprit, an H2/H4 agonist, mimicked
the effects of histamine, and the extents of the decreased
proteinuria and crescent formation were similar to those in
animals treated with histamine (20 mg/kg). Clozapine, an
H4 agonist, tended to alleviate proteinuria and decrease
crescentic formation, although the effects were not statisti-
cally significant (Figure 6).
Effects of histamine receptor antagonists
Administration of mepyramine, an H1 antagonist, did not
influence the beneficial effects of histamine, and there were
no remarkable differences in the magnitude of proteinuria
or the percentage of crescentic glomeruli (Figure 7). Similar
findings were observed in histamine-injected rats treated
with ranitidine, an H2 antagonist. Hence, blockade of neither
H1 nor H2 receptors reversed the protective effect of
histamine.
a b
Figure 4 | Representative photomicrographs of ED-1
immunopositive cells (macrophages/monocytes). (a) Six days after
injection of anti-GBM antibody, infiltration of macrophages was
observed in glomeruli. (b) Treatments with histamine (20 mg/kg)
twice a day decreased the number of macrophages. Bar¼ 100 mm.
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Figure 5 | Effects of histamine treatment on proteinuria. After
injection of anti-GBM antibody, histamine was administered twice a
day. Proteinuria was evaluated 5–6 days after antibody injection.
Values represent the mean7s.d. of 5–8 animals. *Po0.01 as
compared to the antibody-injected control group.
*
Pr
ot
ei
nu
ria
 (m
g/d
ay
)
Saline ClozapineDimaprit
Anti-GBM antibody
Saline ClozapineDimaprit
Anti-GBM antibody
0
50
40
30
20
10
*
Cr
es
ce
n
tic
 g
lo
m
er
ul
i (%
)
0
50
40
30
20
10
Figure 6 | Effects of histamine receptor agonists. Effects of
dimaprit, an H2/H4 agonist, and clozapine, an H4 agonist, were
evaluated. (a) After injection of anti-GBM antibody, saline, dimaprit
(10 mg/kg), or clozapine (10 mg/kg) was administered twice a day.
Proteinuria was evaluated 5–6 days after antibody injection. (b) The
percentage of crescentic glomeruli was determined 6 days after
antibody injection. Values represent the mean7s.d. of 8–14 animals.
*Po0.01 as compared to the antibody-injected control group.
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Figure 7 | Effects of histamine receptor antagonists. Effects of
mepyramine, an H1 antagonist, and ranitidine, an H2 antagonist, were
evaluated in histamine-treated rats. (a) After injection of anti-GBM
antibody, saline, mepyramine (3 mg/kg), or ranitidine (10 mg/kg) was
injected twice a day followed by histamine (20 mg/kg) administration.
Proteinuria was evaluated 5–6 days after antibody injection. (b) The
percentage of crescentic glomeruli was determined 6 days after
antibody injection. Values represent the mean7s.d. of 5–8 animals.
*Po0.01 as compared to the antibody-injected control group. Mepy,
mepyramine; Rani, ranitidine.
610 Kidney International (2007) 72, 608–613
o r i g i n a l a r t i c l e S Tanda et al.: Histamine ameliorates anti-GBM glomerulonephritis
DISCUSSION
Results of this study showed alleviation of proteinuria and
crescent formation in glomeruli by treatment with histamine
or dimaprit. Microscopic and immunohistochemical evalua-
tion showed amelioration of immune injury by treatment
with histamine. These findings indicate that histamine
alleviates the development of renal injury in anti-GBM
glomerulonephritis.
Proteinuria is an early symptom of renal injury, and its
severity reflects glomerular damage. In this study, the
magnitude of proteinuria was correlated with the morpho-
logic outcome. As the beneficial effects of histamine on
proteinuria and crescent formation were reversed by neither
H1 nor H2 blockade, the protective effects may not be
attributed to either histamine H1 or H2 action. The histamine
H4 receptor has recently been reported in humans, mice,
rats, and guinea-pigs.13–17 Although its closest subtype is the
histamine H3 receptor, the expression of histamine H4
receptors differs from that of histamine H3 receptors.
Although histamine H3 receptors are expressed primarily in
the brain, histamine H4 receptors are expressed in peripheral
tissues, particularly, those of hematopoietic lineage, such as
bone marrow, spleen, thymus, and leukocytes.10 For these
reasons, it is unlikely that histamine H3 action contributed to
observed effects.
Although dimaprit was used as an H2 agonist, it has been
shown to possess H4 agonistic activity.
18 As it is unlikely that
histamine H2 action contributed to the alleviation, histamine
H4 receptor activity may have participated in the observed
effects. Clozapine, an H4 agonist, tended to suppress
proteinuria and crescent formation, although the effects of
the agent were less than those of histamine or dimaprit. Taken
together with these findings, histamine H4 receptor stimula-
tion may prevent immune renal injury, at least, in part.
Deposition of antibody on the GBM recruits neutrophils
and macrophages to glomeruli. These leukocytes bind to
antibody and play a pathogenic role in antibody-mediated
glomerulonephritis. Immunofluorescence results in this
study showed a linear deposition of antibody along the
GBM in both the antibody-injected control and histamine-
treated groups. Despite successful deposition of antibody on
the GBM, deposition of complement C3 was not observed in
glomeruli, suggesting another mechanism besides comple-
ment. Similar findings were reported in a previous study, in
which nephritogenicity was examined in nephritis induced
by passive transfer of anti-GBM antibody.19 In the study,
complement C3 deposition was not found in glomeruli as
well as in this study. Recently, CD4þ T lymphocytes specific
to the NC1 of type IV collagen have been demonstrated to
induce anti-GBM glomerulonephritis in Wistar-Kyoto
rats.20,21 In addition, a short linear peptide was identified
as a potent core of a nephritogenic T-cell epitope and
sufficient to induce severe glomerulonephritis without
detectable levels of circulating anti-GBM antibodies.22 These
suggest a mechanism for anti-GBM glomerulonephritis
different from humoral immunity.
Naive CD4þ T cells differentiate into Th1 or Th2 cells,
both of which play important roles in the pathogenesis of
inflammatory disease and allergy. Th1 cells promote cell-
mediated immunity by producing interferon-g and tumor
necrosis factor-a, whereas Th2 cells are involved in humoral
immunity.23 When macrophages are activated, they secrete
IL-12, which stimulates the differentiation of CD4þ -helper
T cells into interferon-g-producing Th1 cells. Secreted
interferon-g further facilitates IL-12 production by macro-
phages, thus, resulting in a positive amplification loop. In
this study, treatments with histamine reduced production
of IL-12. The decrease in the IL-12 level may be due to
histamine H4 activity, because histamine H4 receptor
stimulation has been reported to inhibit the production of
IL-12.10 Furthermore, histamine H4 receptors are expressed
at significant levels in dendritic cells, potent antigen-
presenting cells, which mediate the polarization of naive
T cells.8,24 Thus, the decrease in IL-12 level may have
contributed to the observed effects by suppressing macro-
phage migration.
Histamine has been demonstrated to alleviate ischemia-
induced brain damage. In cerebral ischemia, brain damage
progresses even after recovery of cerebral blood flow, and
inflammatory cell infiltration plays a major role in the
development of reperfusion injury. Postischemic treatments
with L-histidine, a precursor of brain histamine suppressed
inflammatory cell infiltration during reperfusion and alle-
viated the outcome.25–27 The protective effect of L-histidine
may be attributed to suppression of inflammatory reactions
through central histamine H2 receptors, because intracer-
ebroventricular administration of ranitidine, an H2 blocker,
completely reversed the protective effects of L-histidine.25 In
this study, however, the protective effects of histaminergic
ligands were not reversed by H2 blockade. Therefore, the
molecular mechanism underlying the protection may be
different between cerebral ischemia and glomerulonephritis.
Histamine alters capillary function in inflammation,
and several studies have examined the effects of histamine
on renal function. Histamine has been reported to decrease
glomerular permeability, and concurrent infusion of H1
antagonists has been reported to abolish the detrimental
effect of histamine, showing aggravation of renal function
by histamine H1 action.
28 Another study examined the effect
of histamine receptor antagonists in the alteration of
glomerular ultrafiltration after administration of anti-GBM
antibody. H2 blockade by cimetidine decreased the glomer-
ular permeability coefficient 45 min after antibody adminis-
tration.29 Although histamine exerts early changes in renal
function, it may provide benefits by suppressing cell-
mediated cytotoxicity.
In conclusion, histamine ameliorated anti-GBM glomer-
ulonephritis, and histamine H4 action may partly participate
in this amelioration by modulating the Th1/Th2 cytokine
balance. Although anti-immune agents, such as glucocorti-
coids and cyclophosphamide, are used clinically to prevent
the development of immune renal injury, these drugs cause
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serious adverse effects. Combination therapy with histami-
nergic ligands may provide a new strategy for the treatment
of crescentic glomerulonephritis such as that in anti-GBM
glomerulonephritis.
MATERIALS AND METHODS
Animals
Experiments in this study were conducted according to the
Guidelines for Laboratory Animal Experiments of Kyoto Prefectural
University of Medicine. Female Wistar-Kyoto/izm inbred rats,
weighing 130–150 g, were purchased from Shimizu Laboratory
Supplies (Kyoto, Japan) and housed in a temperature-controlled
room at 24711C. Food and water were provided ad libitum. Before
intraperitoneal injection of anti-GBM antibody, the animals were
fasted overnight to minimize the incidence of the bowel perforation.
Reagents
Histamine, mepyramine maleate, ranitidine hydrochloride, dimaprit
dihydrochloride, and clozapine were purchased from Sigma-Aldrich
(St Louis, MO, USA). Dose was expressed as the weight of the free
base. Monoclonal antibody against rat macrophages (ED-1) was
purchased from Serotec (Kidlington, UK). EnVision Plus Reagents
were purchased from Dako Japan (Kyoto, Japan).
Anti-GBM antibody
A homologous monoclonal antibody against the NC1 domain of the
rat type IV collagen (MAb35), which belongs to an IgG2b subclass,
was generated at Shigei Medical Research Institute (Okayama,
Japan). Injection of 3 mg of MAb35 in WKY/NCj rats has been
shown to induce proteinuria, the severity of which peaks at 5
days.19,30 We injected 50 mg of the antibody intraperitoneally per rat.
In a preliminary experiment, endocapillary infiltration of several
mononuclear cells was observed in each glomerulus 2–3 days after
injection of anti-GBM antibody. However, neutrophil infiltration
was slight. Formation of crescentic glomeruli began to appear 3 days
after antibody injection, and the magnitude of crescentic formation
increased thereafter. Endocapillary proliferation, severe fibrinoid
necrosis, and marked crescent formation were identified 6 days after
antibody injection.
Histologic evaluations
Tissue samples obtained from kidneys were fixed in 4% parafor-
maldehyde. After dehydration in graded concentrations of ethanol,
samples were embedded in paraffin. Four-micrometer-thick sections
were generated and stained with periodic acid-methenamine silver
and periodic acid-Schiff. We defined crescentic glomeruli as lesions
consisting of proliferating epithelial and inflammatory cells filling
part or all of Bowman’s space and lesions consisting of at least two
layers of cellular proliferation. Numbers of crescentic glomeruli were
quantified by counting 100 glomeruli in each section. Percentages of
crescentic glomeruli were determined in a single-blinded manner.
Direct immunofluorescence
Kidneys were embedded in 22-oxacalcitriol compound and frozen in
liquid nitrogen. Five-micrometer-thick sections were cut with a
cryostat and washed with phosphate-buffered saline. Sections were
incubated in fluorescein isothiocyanate-conjugated goat antibody
against rat IgG (Zymed Laboratories, San Francisco, CA, USA) or
complement C3 (MP Biomedicals, Aurora, OH, USA) for 30 min
and were observed by fluorescence microscopy.30
Immunohistochemistry
Renal samples were fixed with 4% paraformaldehyde, embedded in
paraffin, and sectioned. Deparaffinized sections for antigen retrieval
were immersed in 500 ml of 0.01 M sodium citrate buffer pH 6.0 and
microwaved in a domestic microwave oven (500 W) for 10 min.
Then, the sections were incubated in 3% hydrogen peroxide to
quench endogenous peroxidase activity. The sections were incubated
sequentially in normal goat serum (1:60) for 20 min, monoclonal
antibody against rat macrophages (ED-1, 1:500) for 1 h, and
horseradish peroxidase-conjugated goat anti-mouse IgG (EnVision
Plus Reagents) for 30 min. Peroxidase reaction product was
visualized by incubation in 0.5 mg/ml 3,30-diaminobenzidine
tetrahydrochloride in 0.01% hydrogen peroxide. Cell nuclei stained
with these antibodies were counted in 50 glomeruli in each section.
IL-12
The plasma concentration of IL-12 was determined by enzyme-
linked immunosorbent assay (BioSource International, Camarillo,
CA, USA).
Experimental procedures
Glomerulonephritis was induced by a single injection of anti-GBM
antibody (Figure 1). After antibody injection, saline or histaminergic
ligands were administered subcutaneously twice a day for 5 days.
Functional damage was evaluated by assessing proteinuria in urine
samples collected for 24 h in metabolic cages 5–6 days after antibody
injection. Tail arterial blood pressure was photoplethysmographi-
cally measured using a model MK-2000 sphygmomanometer
(Muromachi Kikai, Tokyo, Japan). Rats were then anesthetized
with diethylether. After making an abdominal incision along the
anterior transverse line, the left kidney was dissected for immuno-
fluorescence experiments, and a blood sample was collected. After
perfusion fixation with 4% paraformaldehyde, the right kidney was
dissected for histology and immunohistochemistry.
Effects of histamine
Thirty-one rats were assigned to one of five groups: the intact
group (n¼ 5), antibody-injected group (n¼ 8), histamine (5 mg/
kg)-treated antibody-injected group (n¼ 5), histamine (20 mg/kg)-
treated antibody-injected group (n¼ 8), or histamine (50 mg/kg)-
treated antibody-injected group (n¼ 5). Glomerulonephritis was
induced by injection of anti-GBM antibody in the antibody-injected
groups, and the severity of proteinuria and the percentage of
crescentic glomeruli were compared after 6 days (Figure 1).
Infiltration of macrophages was evaluated by ED-1 immunohisto-
chemistry in seven of eight antibody-injected and five of eight
histamine (20 mg/kg)-treated animals. Deposits of anti-GBM anti-
body and complement C3 were assessed by direct immunofluores-
cence. The plasma concentration of IL-12 was determined in 15
animals from the intact, antibody-injected, and histamine (20 mg/
kg)-treated groups (n¼ 5, each).
Effects of histamine receptor agonists
Effects of dimaprit, an H2/H4 agonist, and clozapine, an H4
agonist, on anti-GBM glomerulonephritis were evaluated. Thirty-six
rats were assigned to one of three groups: the antibody-injected
group (n¼ 14), dimaprit-treated antibody-injected group (n¼ 8),
or clozapine-treated antibody-injected group (n¼ 14). Glomerulo-
nephritis was induced in all animals by injection of anti-GBM
antibody. Saline, dimaprit (10 mg/kg), or clozapine (10 mg/kg) was
administered subcutaneously twice a day (Figure 1). The severity of
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proteinuria and the percentage of crescentic glomeruli were then
compared among groups.
Effects of histamine receptor antagonists
The effects of mepyramine, an H1 antagonist, and ranitidine, an H2
antagonist, were examined in histamine-treated rats. Twenty-five
rats were assigned to one of four groups: the saline-injected group
(n¼ 7), histamine-treated group (n¼ 8), mepyramine plus hista-
mine-treated group (n¼ 5), or ranitidine plus histamine-treated
group (n¼ 5). In this experiment, glomerulonephritis was induced
in all animals by intraperitoneal injection of anti-GBM antibody
(Figure 1). Saline, mepyramine (3 mg/kg), or ranitidine (10 mg/kg)
was injected subcutaneously twice a day 1 h before each adminis-
tration of histamine (20 mg/kg). The severity of proteinuria and
the percentage of crescentic glomeruli were compared as described
above.
Statistical analysis
Statistical differences were analyzed by analyses of variance followed
by Scheffe´’s tests.
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